IGC PharmaIGC +3.04%29 PB Ratio is 4.37 as of Jun. 30, 2026, which is 126% above its 10-year median of 1.93. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,229 Biotechnology companies, IGC Pharma ranks worse than 65.91% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-30), IGC Pharma's share price is $0.271. IGC Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $0.06. Hence, IGC Pharma's PB Ratio of today is 4.37.
The historical rank and industry rank for IGC Pharma's PB Ratio or its related term are showing as below:
IGC'
s PB Ratio Range Over the Past 10 Years
Min: 0.35 Med: 1.93 Max: 26.43
Current: 4.37
During the past 13 years, IGC Pharma's highest PB Ratio was 26.43. The lowest was 0.35. And the median was 1.93.
IGC's PB Ratio is ranked worse than 65.91% of 1229
companies
in the Biotechnology industry
Industry Median: 2.86
vs IGC: 4.37
During the past 12 months, IGC Pharma's average Book Value Per Share Growth Rate was -20.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -45.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -38.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -15.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of IGC Pharma was 37.80% per year. The lowest was -52.70% per year. And the median was -31.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
IGC Pharma PB Ratio Related Terms
IGC Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for IGC Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IGC Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where IGC Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
IGC Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
IGC Pharma (IGC) has a PB Ratio of 4.37 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IGC Pharma and its competitors. This is 126% above median its historical median of 1.93. Over the past decade, IGC Pharma's PB Ratio has ranged from 0.35 to 26.43. According to the industry distribution chart, IGC Pharma ranks #810 out of 1229 companies in the Biotechnology industry, placing it in the top 65.9%.
Is IGC Pharma's PB Ratio too high?
IGC Pharma's current PB Ratio of 4.37 is 126% above median its 10-year median of 1.93. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 26.43. The Biotechnology industry median PB Ratio is 2.86. IGC Pharma's value of 4.37 is 52.8% above this industry median. Based on the distribution chart, IGC Pharma ranks #810 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's PB Ratio compare to SER and NRSN?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #810 out of 1229 companies for PB Ratio. This places IGC Pharma in the lower half of its industry. The industry median PB Ratio is 2.86. IGC Pharma's value of 4.37 is 52.8% above this benchmark. Historically, IGC Pharma's own PB Ratio has ranged from 0.35 to 26.43 over the past decade. While the company's 10-year median is 1.93 vs. the industry median of 2.86, IGC Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current PB Ratio of 4.37 is 52.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current PB Ratio is 4.37, which is 126% above median its own 10-year median of 1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 12.9% above its estimated fair value. The current PB Ratio is 4.37, which is 126% above median its 10-year median of 1.93 and 52.8% above the Biotechnology industry median of 2.86. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For IGC Pharma (IGC), the current PB Ratio is 4.37 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.27 is trading 12.9% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
PB Ratio: 4.37 (126% above median its 10-year median of 1.93)
GF Value™: $0.24 vs. price of $0.27 (12.9% above fair value)
Industry Position: 52.8% above the Biotechnology median (#810 of 1229)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
